Stack
BPC-157 and TB-500
The most commonly run repair pairing. Two compounds on different schedules, on the reasoning that one builds blood supply and the other moves cells into the gap.
This is the combination people mean when they say 'the healing stack'. BPC-157 daily, TB-500 weekly, for six to eight weeks around an injury.
The reasoning is mechanistically coherent: BPC-157 is associated with angiogenesis in animal models and TB-500 with cell migration, so the argument is that repair needs both new blood supply and cells arriving to use it. What does not exist is a study of the combination. Both compounds are supported by animal work alone, and combination evidence is weaker than single-compound evidence.
The schedules genuinely differ, which is the main argument for running these separately rather than buying them pre-mixed. TB-500's long half-life suits weekly dosing; BPC-157's does not.
The schedule
Commonly run, not recommended8 weeks. Doses are what sources describe rather than what we advise — where a source gave a range we show the range instead of choosing a number inside it.
| Compound | Dose | How often | Weeks |
|---|---|---|---|
| BPC-157PreclinicalDaily throughout. Associated with new blood supply to injured tissue. | 200 mcg–500 mcg | 2× dailyOften split morning and evening. Frequently injected near the injury, though nothing establishes that local injection outperforms systemic. | 1–8 |
| TB-500PreclinicalWeekly loading, then maintenance. Associated with cell migration into damaged tissue. | 2 mg–5 mg | Weekly · MonCommonly described as a higher loading dose for the first four weeks, halved thereafter. | 1–8 |
Things worth knowing
- Neither compound has human efficacy data. Running two preclinical compounds together does not produce clinical evidence.
- Both are prohibited in sport at all times under WADA S2.
- Injecting near an injury is common practice and is not established as better than injecting anywhere else.
- An eight-week course is a convention, not a finding. Nothing establishes an optimal duration.
- Buying these pre-mixed forces both onto one schedule, which suits neither.
Related
Questions
- Can BPC-157 and TB-500 go in the same syringe?
- People do mix them, and the schedules are the argument against it: BPC-157 is dosed daily and TB-500 weekly, so combining them in one draw forces one of the two onto the wrong frequency. Reconstituting separately keeps each on its own schedule and lets you stop one without stopping both.
- Is the pre-mixed blend the same thing?
- No. A blend is one vial at a fixed ratio, so choosing a dose of one compound chooses the dose of the other. You cannot run daily BPC-157 and weekly TB-500 out of a single vial. Blends are cheaper and less flexible, and that trade is the whole decision.
- Do you need both?
- Nothing establishes that you do. The argument for the pair is mechanistic: new blood supply plus cells arriving to use it. Nobody has tested it against either compound alone in a human. Running both makes it impossible to tell which, if either, did anything.
- Does injecting near the injury help?
- It is very commonly described and it is not established. No study shows local injection outperforming systemic for either compound, and the animal work these are based on used systemic administration.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.